ID   K562/Adr
AC   CVCL_3827
AS   CVCL_2808
SY   K562/adr; K-562adr; K562adr; K562/ADM
DR   BTO; BTO:0002554
DR   CLO; CLO_0050121
DR   GEO; GSM827221
DR   RCB; RCB1898
DR   TKG; TKG 0211
DR   Wikidata; Q54899403
RX   PubMed=3091555;
RX   PubMed=20215515;
CC   Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Adriamycin).
CC   Sequence variation: BCR-ABL1 gene fusion (from parent cell line).
CC   Sequence variation: Homozygous for TP53 p.Gln136fs*13 (c.406_407insC) (from parent cell line).
CC   Omics: SNP array analysis.
CC   Derived from sampling site: Pleural effusion.
ST   Source(s): JCRB; RCB; TKG
ST   Amelogenin: X
ST   CSF1PO: 9,10
ST   D13S317: 8
ST   D16S539: 11,12
ST   D5S818: 11,12
ST   D7S820: 9,11
ST   TH01: 9.3
ST   TPOX: 8,9
ST   vWA: 16
DI   NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
DI   ORDO; Orphanet_521; Chronic myeloid leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens
HI   CVCL_0004 ! K-562
SX   Female
AG   53Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 12-03-20; Version: 18
RX   PubMed=3091555; DOI=10.20772/cancersci1985.77.7_682;
RA   Tsuruo T., Iida-Saito H., Kawabata H., Oh-hara T., Hamada H.,
RA   Utakoji T.;
RT   "Characteristics of resistance to adriamycin in human myelogenous
RT   leukemia K562 resistant to adriamycin and in isolated clones.";
RL   Jpn. J. Cancer Res. 77:682-692(1986).
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).